KEI Comments: ERYTHRYx Therapeutics: Prospective Grant of an Exclusive Patent License on Methods of Modulating Erythropoiesis With Arginine Vasopressin Receptor 1B Molecules

UPDATE: On July 13, 2019, KEI received a response to our comments on the prospective license to be given to ERYTHRYx Therapeutics. The brief response simply stated that NIH had already assessed the company to meet their technical and financial… Continue Reading